BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 2129104)

  • 1. Comparative analysis of natural killer function in lung, spleen, and peripheral blood lymphocytes: evidence of differential characteristics.
    Lauzon W; Yang H; Lemaire I
    Reg Immunol; 1990-1991; 3(3):145-50. PubMed ID: 2129104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of biological response modifiers on lung natural killer activity.
    Lauzon W; Lemaire I
    Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of in vitro hyperthermia on natural killer activity from lung, blood and spleen.
    Yang H; Mitchel R; Lemaire I
    J Clin Lab Immunol; 1990 Jul; 32(3):117-22. PubMed ID: 1726330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allospecific recognition of hemic cells in vitro by natural killer cells from athymic rats: evidence that allodeterminants coded for by single major histocompatibility complex haplotypes are recognized.
    Vaage JT; Dissen E; Ager A; Fossum S; Rolstad B
    Eur J Immunol; 1991 Sep; 21(9):2167-75. PubMed ID: 1716212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.
    Wiltrout RH; Herberman RB; Zhang SR; Chirigos MA; Ortaldo JR; Green KM; Talmadge JE
    J Immunol; 1985 Jun; 134(6):4267-75. PubMed ID: 3989307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
    Knoblock KF; Canning PC
    Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex.
    Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Noguchi K; Mizobata S; Tamai M; Hotta T; Arii K
    Anticancer Res; 1994; 14(4A):1557-62. PubMed ID: 7979185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
    Wiltrout RH; Pilaro AM; Gruys ME; Talmadge JE; Longo DL; Ortaldo JR; Reynolds CW
    J Immunol; 1989 Jul; 143(1):372-8. PubMed ID: 2732472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
    Brooks CG; Holscher M; Urdal D
    J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells in the thymus. Studies in mice with severe combined immune deficiency.
    Garni-Wagner BA; Witte PL; Tutt MM; Kuziel WA; Tucker PW; Bennett M; Kumar V
    J Immunol; 1990 Feb; 144(3):796-803. PubMed ID: 2136898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.